title: Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide.
abstract: OBJECTIVE
  The antiemetic effectiveness of ondansetron 8 mg i.v, ondansetron 32 mg i.v, and granisetron 10 microg/kg or 1 mg i.v. as prophylaxis in breast cancer patients regimens was studied.
  
  
  METHODS
  Data from six U.S. cancer centers were collected retrospectively for 224 patients who received cyclophosphamide-containing therapy between January 1998 and June 2002. Logistic-regression analysis was used to examine the likelihood of chemotherapy-induced nausea and vomiting (CINV) both on an unadjusted basis and controlling for concomitant radiation therapy and dexamethasone use.
  
  
  RESULTS
  Seventy-six patients (34%) received ondansetron 32 mg, 68 (30%) received ondansetron 8 mg, and 80 (36%) received granisetron (either 10 microg/kg or 1 mg). Patients receiving ondansetron 8 mg were 2.5 times as likely to have CINV on an adjusted basis as granisetron recipients (p < 0.01). There was no increase in the risk of CINV with ondansetron 32 mg compared with granisetron. Patients treated with ondansetron 8 mg required more rescue antiemetics and more prophylactic antiemetics in subsequent chemotherapy cycles than patients in the other groups.
  
  
  CONCLUSIONS
  In a retrospective multicenter study, granisetron 1 mg or 10 microg/kg and ondansetron 32 mg appeared more effective than ondansetron 8 mg in preventing acute CINV related to cyclophosphamide therapy.
authors.affiliation: EPI-Q, Inc., Oakbrook Terrace, IL 60181, USA.
authors.forename: Cindy L
authors.initials: CL
authors.lastname: Dempsey
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Coop
authors.forename: Alicia
authors.initials: A
authors.lastname: Shillington
authors.forename: P Anne
authors.initials: PA
authors.lastname: Farley
authors.forename: Douglas R
authors.initials: DR
authors.lastname: Eberhardt
authors.forename: Sharon
authors.initials: S
authors.lastname: O'Briant
mesh_terms: D000328:Adult; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002173:Cancer Care Facilities; D015331:Cohort Studies; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D017829:Granisetron / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D016015:Logistic Models; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D003907:Dexamethasone; D017829:Granisetron; D017294:Ondansetron